Pharmacology in Medical Technology

Covance Receives Highest Level of Phase I Accreditation

... accreditation for the conduct of clinical pharmacology in Europe by the Medicines and Healthcare ... practice inspections. Covance's clinical pharmacology expertise includes full-time physicians, clinical ... The industry leader in the conduct of clinical pharmacology studies, Covance offers more than 500 beds across ...

MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting

... data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine ... Meeting in Boston, MA. In this receptor pharmacology study, MAP0004 stimulated receptors that relieve ... entitled "Improved Dihydroergotamine (DHE) pharmacology Following Orally-Inhaled Delivery." In addition ...

PAREXEL Expands Global Clinical Pharmacology Capabilities

... had completed the expansion of three Clinical pharmacology Research Units located in Baltimore, Maryland in ... combined with an integrated global clinical pharmacology presence has been a cornerstone of ... activities." In Baltimore, PAREXEL's Clinical pharmacology Research Unit has been expanding capabilities and ...

Medpace Opens Clinical Pharmacology Unit in Cincinnati, Ohio

... organization (CRO), is opening a 50 bed clinical pharmacology unit in Cincinnati, Ohio. The Medpace ... as a Senior Reviewer in the Office of Clinical pharmacology for almost 10 years where he was heavily ... specialized testing Medpace Clinical pharmacology -- a Phase I/IIa unit View the Medpace website ...

Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies

... -- Covance Inc. today announced its integrated radiolabeled clinical pharmacology studies in compliance with Food and Drug Administration (FDA) guidance on ... help reduce the time and cost of drug development by integrating clinical pharmacology AME study conduct and data management services with bioanalytical ...

One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials

... of Chemistry and Chemical Biology, along with Jean Bidlack, professor of pharmacology and physiology at the University of Rochester , and members of her pharmacology group, and funding by the National Institutes of Health. "I didn't do ...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

... in preclinical and clinical studies," said Dr. Philip Thorpe, professor of pharmacology at UT Southwestern Medical Center in Dallas, a scientific advisor to ... T-cell proliferation. Dr. Xianming Huang, assistant professor of pharmacology at UT Southwestern Medical Center and lead author of the study, noted, ...

NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients

... osteoarthritis (OA) patients with controlled hypertension in two clinical pharmacology studies in the United States, in line with previously announced timelines. ... commented: "We are very pleased to have fully enrolled these two clinical pharmacology studies and we look forward to their results in the fourth quarter of this ...

Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV

... mechanism for the treatment of chronic hepatitis C. Based on preclinical pharmacology testing and the results of completed 13-week GLP animal toxicology ... prodrug of a novel TLR7-specific agonist. Results from pre-clinical pharmacology studies have shown that ANA773 can elicit desired immune responses and ...

DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin

... DCGN ) today announced positive topline results from its latest clinical pharmacology study of DG041, the company's first-in-class antagonist of the EP3 ... of EP3. In Phase I and Phase IIa clinical trials and follow-on clinical pharmacology studies, DG041 has been shown to dramatically inhibit platelet aggregation ...

Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials

... efficiently and quickly. Barry Mangum, PharmD, FCP, director of clinical pharmacology for the DCRU and associate clinical professor of clinical pharmacology at Duke University Medical Center, says the proprietary ALPHADAS software ...

TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

... Vice Chairman for Research, Department of Anesthesiology, and Professor of pharmacology at the University of California, San Diego Dr. Yaksh will present ... chronic pain therapy. The focus of his research is the physiology and pharmacology of pain processing. A member of numerous professional societies, Dr. ...

FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008

... of the IND submission, Arisaph completed comprehensive nonclinical safety pharmacology and toxicology studies, including 28 day toxicology studies in rats and primates. The results show that ARI-2243 has a favorable safety pharmacology profile and has a high therapeutic index. Based on the preclinical ...

HUYA Bioscience Int'l Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China

... medicine over the past decade; Benedict R. Lucchesi, Ph.D., Professor of pharmacology at the University of Michigan Medical School Department of pharmacology for more than 40 years and contributor to more than 370 publications in ...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

... July 21 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that researchers from the Laboratory of Molecular pharmacology at the National Cancer Institute presented new preclinical research identifying unique anti-tumor mechanisms of brostallicin that sets this agent ...

UNT Health Science Center's Groundbreaking Research Applied to Protecting Brain After Traumatic Injury

... are now being tested on human trauma patients in North Texas. James Simpkins , Ph.D., UNT Health Science Center chair of the Department of pharmacology and Neuroscience, and Jane Wigginton , M.D., Department of Surgery, Division of Emergency Medicine at UT Southwestern Medical Center of Dallas, ...

Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug

... About Cordex Pharma, Inc. Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the ...

Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)

... leukemia (SLL). The objectives of the Phase 1 TRU-016 CLL study were to define safety and tolerability, identify a maximum tolerated dose, evaluate pharmacology and pharmacodynamics, and assess preliminary clinical activity. Patients received either one dose weekly for four weeks, or three doses the first ...

New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer

... potency of these antidepressants as CYP2D6 inhibitors. This lends biological plausibility to the data," added Dr. David Flockhart, chief of clinical pharmacology at Indiana University School of Medicine and a member of the research team. Study Details The study was a retrospective analysis of ...

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

... are more closely related to their blood pressure levels than to their blood sugar levels," said Joseph L. Izzo, Jr., M.D., Professor of Medicine and pharmacology at SUNY-Buffalo and Director of Medicine at the Erie County Medical Center in Buffalo. "In ROADMAP, to date, we have achieved some of the lowest BP ...

Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference

... was supervised by Angelika Burger, Ph.D., director of the Translational Research Laboratory at the Karmanos Cancer Institute and professor of pharmacology at Wayne State University in Detroit. Karri Stark, a doctoral candidate with Wayne State University's School of Medicine, presented the findings. ...

VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis

... for allergic diseases, regardless of the antigen responsible for the allergic response. The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-1463 in healthy volunteers and will help define the appropriate dose(s) for a proof of concept clinical study in allergic ...

Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions

... Co., where she led an in vitro toxicology research program, and then served as Manager of Technology and Planning. Dr. Arterburn received her PhD in pharmacology and the Molecular Sciences from the Johns Hopkins University School of Medicine , and her Bachelor's Degree in Biochemistry from the University of ...

New, Published GELNIQUE Data Show Efficacy, Convenience and Excellent Tolerability

... 400 (0.3 percent) given placebo discontinued treatment due to skin reactions. There was no severe erythema observed in the trial. Additional pharmacology studies showed that showering one hour or later, or the application of sunscreen 30 minutes before or after GELNIQUE application did not ...

Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours

... The Principal Investigator is Dr. Miguel Villalona-Calero, Professor, Division of Hematology/Oncology and Department of Internal Medicine and pharmacology at The Ohio State University Comprehensive Cancer Center. "We are quite excited about this trial, since there are no known therapies that to date ...

Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma

... versus conventional formulations of prostaglandin analogues: an in vivo toxicity assay" at the 9th Scientific Meeting of the Association for Ocular pharmacology and Therapeutics (AOPT) held in Salzburg, Austria. The experimental work has been performed in collaboration with Professor Christophe Baudouin from ...

ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease

... Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, Schweighoffer F, Desire L. Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing. Journal of Neurochemistry. 2008; 106: 392-404 [2] Pando M, Marcade M, Peillon H, Rayer A, Drouin D, ...

Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures

... About Cordex Pharma, Inc. Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the ...

Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis

... than the control group as well as reduced aortic valve calcification. Results of the study were published in April 2008 in the British Journal of pharmacology . "We are very pleased to add this exciting new intellectual property to our growing portfolio of HDL therapies," said Jean-Louis Dasseux, ...

Duska Therapeutics Completes Corporate Name Change to Cordex Pharma

... About Cordex Pharma, Inc. Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the ...

Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... were tested. The magnitude of these effects is larger than that seen with other drugs of this class and may be attributed to additional beneficial pharmacology that emerges at the higher doses tested. At the highest dose tested (10 mg) we expect to have full occupancy of 5HT2A receptors while adding ...

NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis

... intervals (CIs). In contrast, naproxen 500 mg bid raised SBP compared to placebo (p<0.001). Garret FitzGerald, MD, Professor of Medicine and pharmacology at the University of Pennsylvania School of Medicine, commented: "The present results for naproxcinod reinforce those of previous studies and show ...

VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology

... immune system and provide a valuable addition to various treatment regimens in oncology. The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-2337 in patients with late stage cancer. "VTX-2337 is the first selective TLR8 compound to reach the clinic and we ...

Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology

... CDK6 Primes Myeloma Cells for Synergistic Killing by Proteasome Inhibitors Carfilzomib and PR-047 (Abstract #3670) -- Preclinical pharmacology and in vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome (Abstract #3671) Location: Moscone Center Hall A ...

Duska Therapeutics Applies for Phase 3 Special Protocol Assessment

... ): Duska is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the ...

Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented

... The poster's author is Herbert E. Kaufman, M.D., Ophthalmologist Emeritus of Sirion Therapeutics and formerly Professor of Ophthalmology and pharmacology and Head of the Department of Ophthalmology at LSU Medical Center, and past president of the Association for Research and Vision in Ophthalmology ...

Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate

... 12 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) today announced the publishing of a paper in the journal for the American Society for pharmacology and Experimental Therapeutics, Drug Metabolism and Disposition, entitled "Oxidative In Vitro Metabolism of Liquiritigenin, a Bioactive Compound ...

Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

... double-blinded clinical trials ever conducted in lupus," said Joan T. Merrill, M.D., F.A.C.R., study investigator, and Program Chair, Clinical pharmacology Research Program, Oklahoma Medical Research Foundation. "There is a significant need for new and more effective treatments for these patients, and we ...

Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic

... has scaled up manufacturing of two clinical candidates, IDX136 and IDX316, from its HCV protease inhibitor discovery program to support IND-enabling pharmacology and toxicology studies. Both IDX136 and IDX316 are based on Idenix's proprietary scaffold B and were developed through SAR (structural activity ...

Silence Therapeutics Announces Board Changes

... Development, Ms. Clancy held a number of positions in Clinical Research, R&D project management and Commercialization. Ms. Clancy has a BSc (Hons) pharmacology from Bath University. Jerry Randall has been Chief Financial Officer of Sinclair Pharmaceuticals plc since 2000 when he joined as part of a ...